Efficacy News and Research

RSS

Scaling up the production of customized immune cells for drug development and testing

To prevent testing on animals and create even more precise ways of testing therapeutics, the pharmaceutical industry is increasingly turning to human immune cells.

1 Dec 2022

Study implicates gut microbiome health in Parkinson's disease

A new study published in the journal Nature Communications discusses the links between this condition that affects the brain and changes in the gut microbiome that may predate brain changes.

1 Dec 2022

Using cationic nanonmaterials to target visceral adiposity

Researchers have long been working on how to treat obesity, a serious condition that can lead to hypertension, diabetes, chronic inflammation, and cardiovascular diseases.

1 Dec 2022

Gargling with povidone-iodine may reduce salivary viral load in COVID-19 patients

A prospective, randomized, open-level clinical trial demonstrates that gargling with povidone-iodine accelerates viral clearance and reduces saliva infectivity in patients with asymptomatic or mild coronavirus disease 2019 (COVID-19). The trial findings have been published in the journal Scientific Reports.

1 Dec 2022

Very low-calorie and vegan diets improve glycemic control in type 2 diabetes

Very low-calorie diets and vegan diets improve weight loss and anthropometric markers in type 2 diabetes patients.

1 Dec 2022

Prior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infection

Previous infection with SARS-CoV-2 and booster vaccination protect against ICU admission and mortality following infection with the Omicron variant.

1 Dec 2022

HU begins human trial for promising treatment to reverse paralysis and language disorder after stroke

Hiroshima University started the human trial for a promising treatment that offers hope in potentially reversing paralysis and language disorder after moderate to severe stroke using therapeutically superior mesenchymal stem cells (MSCs) derived from the cranial bone.

1 Dec 2022

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity.

1 Dec 2022

Risk factor assessment for the development of severe SARS-CoV-2 breakthrough infections

researchers evaluated the severity of breakthrough SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections and the risk factors associated with severity among individuals vaccinated for coronavirus disease 2019 (COVID-19) in Sousse, Tunisia.

1 Dec 2022

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

Researchers mutated the SARS-CoV-2 spike protein's trimeric structure to design a novel prefusion S antigen, S2D14.

1 Dec 2022

Researchers explore failed SARS-CoV-2 screening at hospital entrances

Researchers evaluated the failure rates of COVID-19 screening at hospital entrances for visitors, health professionals, and patients at the Yale New Haven Hospital in the US.

1 Dec 2022

The requirement for Fc effector functions to protect against SARS-CoV-2 infection

Researchers determined which specific fragment crystallizable effector functions protect against SARS-CoV-2 infection, especially its emerging variants.

1 Dec 2022

Study reveals key details of how DREADD technology highjacks neuronal activity

Understanding of how neuronal activity modulates brain function is a key first step towards creating more effective drugs to treat a variety of neuropsychiatric illnesses, including depression, anxiety, schizophrenia, substance abuse, epilepsy, and others.

30 Nov 2022

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

30 Nov 2022

New drug candidates for male birth control may be on the horizon

For decades, researchers have been working on "male birth control" - and studies show there is a demand.

30 Nov 2022

Existing drug may help decrease side effects of widely used cancer treatment

A Michigan State University researcher is part of an international team that found an existing drug may help decrease side effects of cisplatin, a widely used cancer treatment that was discovered at MSU in 1965.

30 Nov 2022

Australian researchers unearth a new form of antimicrobial resistance

Australian researchers have uncovered a new form of antimicrobial resistance (AMR) – undetectable using traditional laboratory testing methods – in a discovery set to challenge existing efforts to monitor and tackle one of the world's greatest health threats.

30 Nov 2022

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

A recent study identified neutralizing antibodies against conserved SARS-CoV-2 epitopes.

30 Nov 2022

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new study published in The Lancet Infectious Diseases.

30 Nov 2022

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Researchers investigated the neutralizing antibody titers against the newly emergent BQ.1, BQ.1.1, XBB, and XBB.1 SARS-CoV-2 Omicron subvariants using sera from individuals with primary and booster COVID-19 vaccinations and previous SARS-CoV-2 infections.

30 Nov 2022

Efficacy News and Research

Scaling up the production of customized immune cells for drug development and testing

Study implicates gut microbiome health in Parkinson's disease

Using cationic nanonmaterials to target visceral adiposity

Gargling with povidone-iodine may reduce salivary viral load in COVID-19 patients

Very low-calorie and vegan diets improve glycemic control in type 2 diabetes

Prior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infection

HU begins human trial for promising treatment to reverse paralysis and language disorder after stroke

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

Risk factor assessment for the development of severe SARS-CoV-2 breakthrough infections

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

Researchers explore failed SARS-CoV-2 screening at hospital entrances

The requirement for Fc effector functions to protect against SARS-CoV-2 infection

Study reveals key details of how DREADD technology highjacks neuronal activity

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

New drug candidates for male birth control may be on the horizon

Existing drug may help decrease side effects of widely used cancer treatment

Australian researchers unearth a new form of antimicrobial resistance

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News